XTLB (XTL Biopharmaceuticals) PB Ratio: (As of Jun. 26, 2026)


XTLB XTL Biopharmaceuticals Ltd XTLB
24 GF Score
Price $2.57
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), XTL Biopharmaceuticals's share price is $2.565. XTL Biopharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2025 was $-0.02. Hence, XTL Biopharmaceuticals's PB Ratio of today is .

Good Sign:

XTL Biopharmaceuticals Ltd stock PB Ratio (=1) is close to 2-year low of 0.94.

The historical rank and industry rank for XTL Biopharmaceuticals's PB Ratio or its related term are showing as below:

XTLB' s PB Ratio Range Over the Past 10 Years
Min: 0.94   Med: 2.25   Max: 3.83
Current: 1

During the past 13 years, XTL Biopharmaceuticals's highest PB Ratio was 3.83. The lowest was 0.94. And the median was 2.25.

XTLB's PB Ratio is ranked better than
82.22% of 1232 companies
in the Biotechnology industry
Industry Median: 2.8 vs XTLB: 1.00

During the past 12 months, XTL Biopharmaceuticals's average Book Value Per Share Growth Rate was -100.00% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -14.70% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -15.00% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -10.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of XTL Biopharmaceuticals was 22.10% per year. The lowest was -57.30% per year. And the median was -16.70% per year.

Back to Basics: PB Ratio


XTL Biopharmaceuticals  (NAS:XTLB) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


XTL Biopharmaceuticals PB Ratio Related Terms


XTL Biopharmaceuticals PB Ratio Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals PB Ratio Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.31 2.83 1.65 2.48 3.28

XTL Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.48 5.93 3.28 0.00

XTLB vs VRTX, REGN, ALNY: PB Ratio Comparison

For the Biotechnology subindustry, XTL Biopharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's PB Ratio falls into.


XTLB
24GF Score
XTL Biopharmaceuticals Ltd XTLB
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

XTL Biopharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2025)
=2.565/-0.021
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score

Get the complete analysis for XTLB

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.57
Price